Poster Session and lectures describing HCRI's cancer research.
Poster competitions, based on cancer related research, will be divided into Undergraduate, Masters level, Technician, and Post Doc levels.
Light refreshments will be provided.
- Harper Hall
Keynote Address by Christoph Reinhard, Senior Director, Translational Sciences Oncology, Eli Lilly and Company
Dr. Reinhard has been focused for the last 20 years on oncology drug development in research settings of universities, biotech and pharmaceutical companies. He received his MS in human genetics at the University of Freiburg and subsequently completed his PhD thesis in biochemistry at the Biocenter, Basel, Switzerland. Early research interests focused on signal transduction of apoptosis and TNF signaling as well as translational control mechanisms through the PI3K/Tor pathway. Technology development for target ID and validation for small and large molecules resulted in key patents on new therapeutic targets and novel antisense chemistry. His interests in the first generation genomics approaches developed into a strategic frame work for biomarker and tailored therapeutic implementation including the development of outsourcing networks and pre-competitive consortia in order to streamline disease characterization efforts. Currently, he is heading the Translational Science Oncology effort at Eli Lilly and Company.
- Raclin-Carmichael Auditorium
Lectures on advances in cancer research
- Raclin-Carmichael Auditorium
Reception - Raclin-Carmichael Auditorium
Research Day schedule:
11 a.m. - 2 p.m. Poster Session (over 80 posters from 28 labs)
2 - 3 p.m. Oral presentations from ENSCCII trainees
3 - 4 p.m. Oral presentations from 2013 Advancing Basic Cancer (ABC) Awardees
4 - 4:30 p.m. Kate Volker, Director, RiverBend Cancer Services
4:30 - 5:30 p.m. Keynote: Christoph Reinhard, Senior Director Translational Sciences Oncology, Eli Lilly and Co. "Translational strategies in Oncology"
5:30 - 6 p.m. Poster Awards
6 - 6:45 p.m. Reception
This event is FREE and open to the public.